The American Cancer Society announced a new collaboration with Trial Library, Inc., and the PCCTC to support a national initiative to accelerate the recruitment of Black patients to prostate cancer clinical trials.

Dr McKay won the 2024 Christopher G. Wood Rising Star Award at IKCS Europe, which took place in Sitges, Spain between April 18th and 20th, 2024.

OncoC4, Inc. (“OncoC4”) today announced that the first patient with metastatic castration resistant prostate cancer has been dosed in a PCCTC-managed Phase 1/2 trial evaluating the anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart) in combination with radioligand therapy, lutetium (177Lu) vipivotide tetraxetan (Pluvicto®).

Manuscript published in Cancer Research Communications finds Black participants with advanced prostate cancer reported worse pain than White participants, and more pain was associated with worse survival. More holistic clinical assessments of pain in this population are needed to determine the factors upon which to intervene to improve quality of life and survivorship, particularly for Black individuals.

The PROMISE Registry aims to provide access to germline genetic testing and to collect data to understand disease characteristics and treatment responses across the disease spectrum for prostate cancer with rare germline genetic variants.

Howard I. Scher, MD, sheds light on various research programs he has led or has been heavily involved with that have helped change the course of prostate cancer treatment over the years.

Study shows that LD and higher ADT sensitivity tumors had favorable outcomes. Those with a luminal proliferating subtype, PTEN loss, and/or HRD signatures had poor outcomes despite ADT/radiation and enzalutamide and may benefit from alternative approach.

Combination was safe with improved rPFS, OS duration, and a higher proportion ofPSA declines.

Caris Life Sciences®, the Prostate Cancer Clinical Trial Consortium and Sorrento Therapeutics, Inc. announced a strategic collaboration to guide more precise treatment decisions for patients with advanced prostate cancer.

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB (EXINI), has entered into a collaboration with the Prostate Cancer Clinical Trials Consortium (PCCTC) to advance artificial intelligence (AI)-enabled imaging biomarkers in prostate cancer.

Study published in Clinical Genitourinary Cancer details the first examining radium-223 in pain palliation using standard doses and contemporary pain end points radium-223, and demonstrated radium-223’s ability to palliate pain in a clinically meaningful manner in nearly one-half of enrolled patients.

The Diversity Working Group of the IRONMAN registry has developed informed strategies for site selection, recruitment, engagement and retention, and trial design and eligibility criteria to ensure broad inclusion and needs awareness of minority participants.

Manuscript published in JCO Oncology Practice details practical considerations and challenges for germline genetic testing in patients with prostate cancer

Despite known racial disparities, men of color remain underrepresented in prostate cancer clinical trials